The growth of the biopharmaceuticals market is feeding back into economies and, in part, is driving the boom in life sciences and biotech ecosystems.
naka/Stock.adobe.com
The life sciences industry is seeing a robust trend in biotech incubator spaces geared toward fostering the growth of new and emerging biotech startups. Incubators on a global scale are determined to grow life sciences innovation in tandem with economically developing local regions. In the United States and other countries, life science sectors around the world are invigorated by efforts on the part of various entities—including government, industry, and academia. Working collectively, these entities aim to foster the growth of burgeoning regional biopharmaceutical industries by providing biotech startups space, talent, funding, and resources.
Read this article in BioPharm International’s September 2022 Emerging Therapies 2022 eBook.
Feliza Mirasol is the science editor for BioPharm International.
BioPharm International
eBook: Emerging Therapies 2022, September 2022
September 2022
Pages: 28–33
When referring to this article, please cite it as F. Mirasol, “Biotech Incubators Cultivate a Global Scene," BioPharm International Emerging Therapies 2022 eBook (September 2022).
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Pfizer Obtains Exclusive Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF
July 25th 2025The licensing agreement between the two companies gives Pfizer the rights to develop, manufacture, and commercialize 3SBio’s bispecific antibody, SSGJ-707, which is in clinical trials for the treatment of a variety of cancers.
Mechanistic Hypothesis of Toxicity: Driving Decision Making in Preclinical Translation
July 16th 2025Mechanistic toxicity hypothesis is essential in guiding decision-making and predicting toxicities during the preclinical stages of drug development. The authors highlight the growing importance of integrating advanced technologies like mass spectrometry imaging into toxicology to enhance preclinical translation, foster innovation in therapeutic development, and ultimately improve drug safety and efficacy.